A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. [electronic resource]
Producer: 20171214Description: 47-58 p. digitalISSN:- 1573-0646
- Adult
- Aged
- Antineoplastic Agents -- adverse effects
- Colonic Neoplasms -- drug therapy
- Extracellular Signal-Regulated MAP Kinases -- blood
- Female
- Humans
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- MAP Kinase Kinase 2 -- antagonists & inhibitors
- Male
- Maximum Tolerated Dose
- Melanoma -- drug therapy
- Middle Aged
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- adverse effects
- Pyridones -- adverse effects
- Pyrimidinones -- adverse effects
- Skin Neoplasms -- drug therapy
- Treatment Outcome
- Uveal Neoplasms -- drug therapy
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.